Dyne Therapeutics Says Trial of Potential Duchenne Muscular Dystrophy Drug Shows 'Meaningful' Results
The 32-patient trial is specifically for individuals with the rare genetic disease who are amenable to exon 41 skipping, a type of genetic therapy, the company said.
Improvements were seen for standardized assessments of stride velocity, movement, 10-meter walk or time, and time to rise from floor, the company said.
Dyne said it expects to submit a Biologics License Application submission for accelerated US approval in early 2026.
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
© 1999-2025 Midnight Trader, Inc. All rights reserved.
close
Dyne Therapeutics Says Trial of Potential Duchenne Muscular Dystrophy Drug Shows 'Meaningful' Results
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "
Your e-mail has been sent.
close
Your e-mail has been sent.
Related News
-
What's Going On With Gorilla Technology Stock Monday?
Benzinga - 14 minutes ago
-
Benzinga - 18 minutes ago
-
Vanda Raises Concerns Over FDA Review Timeline for Motion Sickness Therapy Candidate
MT Newswires - 30 minutes ago
-
Bombardier CEO says he fears US could target firm if Canada scraps jet deal
Reuters - 35 minutes ago
-
Cme Group Insider Sold Shares Worth $2,600,000, According to a Recent SEC Filing
MT Newswires - 37 minutes ago
-
Honda, Suzuki to join Tesla's CO2 emissions pool for 2025
Reuters - 45 minutes ago
-
Honda, Suzuki to join Tesla's CO2 emissions pool for 2025
Reuters - 48 minutes ago
Content for this page, unless otherwise indicated with a Fidelity pyramid logo, is selected and published by Fidelity Interactive Content Services LLC ("FICS"), a Fidelity company. All Web pages published by FICS will contain this legend. FICS was established to present users with objective news, information, data and guidance on personal finance topics drawn from a diverse collection of sources including affiliated and non-affiliated financial services publications. Content selected and published by FICS drawn from affiliated Fidelity companies is labeled as such. FICS-selected content provided is not intended to provide tax, legal, insurance, or investment advice, and should not be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by any Fidelity entity or any third party. Quotes are delayed unless otherwise noted. FICS is owned by FMR LLC and is an affiliate of Fidelity Brokerage Services LLC. Terms of use for Third-Party Content and Research
These links are provided by Fidelity Brokerage Services LLC ("FBS") for educational and informational purposes only. FBS is responsible for the information contained in the links. FICS and FBS are separate but affiliated companies and FICS is not involved in the preparation or selection of these links, nor does it explicitly or implicitly endorse or approve information contained in the links.
Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.
